Search - tctmd.com

Displaying 1 - 20 of 250

Sort: Relevancy | Date

News Daily News

JACC Debuts Data Digest on CV Health in the United States

Caitlin E. Cox

January 12, 2026

News Daily News

Weight Regained Within 18 Months of Stopping GLP-1 Drugs

Michael O'Riordan

January 08, 2026

News Daily News

Statins Work for Primary Prevention Even in Low-risk Patients With Type 2 Diabetes

Todd Neale

January 05, 2026

News Daily News

Year in Review: Top Prevention Stories of 2025

Michael O'Riordan

December 24, 2025

News Features

Year in Review: Women’s Heart Health in the Spotlight

Caitlin E. Cox

December 23, 2025

News Daily News

SURPASS-CVOT Published: Large Trial Confirms CVD Efficacy of Tirzepatide

Michael O'Riordan

December 18, 2025

News Conference News TCT 2025

Ultrathin-Strut DES Performs Well vs Xience in Diabetic Patients: TUXEDO-2

Todd Neale

November 03, 2025

News Daily News

Prevention Must Be Prioritized in Heart Failure Care: HFSA/ASPC

Yael L. Maxwell

August 18, 2025

News Daily News

Tirzepatide Matches Dulaglutide in Large CV Outcomes Trial: SURPASS-CVOT

Michael O'Riordan

July 31, 2025

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for July 2025

Caitlin E. Cox

July 31, 2025

Presentation TCT India 2025

Intervention to Prevention

Presenter: Brajesh Mittal

July 26, 2025

Presentation TCT India 2025

No Ctrl+Z in the Cath Lab: Decisions, Disaster, and Deliverance

Presenter: Rajesh Natuva & Ramesh Gudapati

July 26, 2025

Presentation TCT India 2025

Cracking The Calcium OCT Guided Rotablation in Action

Presenter: Annapoorna Kalia

July 26, 2025

Presentation TCT India 2025

Hybrid PCI-Less Metal More Medicine

Presenter: Sanjeev Gera

July 26, 2025

News Daily News

AI Has Great Potential in CV Pharmacotherapy, but Much Work Lies Ahead: Review

Todd Neale

July 24, 2025

News Conference News ACC 2025

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

Michael O'Riordan

March 29, 2025

Presentation ACC 2025

Oral Semaglutide Reduces Cardiovascular Events in People with Type 2 Diabetes with Atherosclerotic Cardiovascular and/or Chronic Kidney Disease: Primary Results From the SOUL Randomized Trial

Presenter: Darren K. McGuire

March 29, 2025

News Daily News

‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials

Michael O'Riordan

February 20, 2025

News Opinion CV Team Dispatch

January 2025 Dispatch for the CV Team

L.A. McKeown

January 24, 2025

News Daily News

Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study

Michael O'Riordan

January 22, 2025

Advertisement

JACC Debuts Data Digest on CV Health in the United States

Weight Regained Within 18 Months of Stopping GLP-1 Drugs

Statins Work for Primary Prevention Even in Low-risk Patients With Type 2 Diabetes

Year in Review: Top Prevention Stories of 2025

Year in Review: Women’s Heart Health in the Spotlight

SURPASS-CVOT Published: Large Trial Confirms CVD Efficacy of Tirzepatide

Ultrathin-Strut DES Performs Well vs Xience in Diabetic Patients: TUXEDO-2

Prevention Must Be Prioritized in Heart Failure Care: HFSA/ASPC

Tirzepatide Matches Dulaglutide in Large CV Outcomes Trial: SURPASS-CVOT

TCTMD’s Top 10 Most Popular Stories for July 2025

Intervention to Prevention

No Ctrl+Z in the Cath Lab: Decisions, Disaster, and Deliverance

Cracking The Calcium OCT Guided Rotablation in Action

Hybrid PCI-Less Metal More Medicine

AI Has Great Potential in CV Pharmacotherapy, but Much Work Lies Ahead: Review

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

Oral Semaglutide Reduces Cardiovascular Events in People with Type 2 Diabetes with Atherosclerotic Cardiovascular and/or Chronic Kidney Disease: Primary Results From the SOUL Randomized Trial

‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials

January 2025 Dispatch for the CV Team

Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content